Results 61 to 70 of about 83,483 (295)

Editorial:Metformin: Beyond Diabetes [PDF]

, 2019
International ...
Bost, Canto, El-Mir, Evans, Ferreira, Foretz, Foretz, Forslund, Hawley, Kaminski, Leung, Madiraju, Martin-Montalvo, Mohan, Neumann, Owen, Patel, Rena, Saxton, Zhou   +19 more
core   +4 more sources

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. [PDF]

, 2019
ObjectiveMicroglia play a pivotal role in the initiation and progression of Alzheimer's disease (AD). We here tested the therapeutic hypothesis that the Ca2+-activated potassium channel KCa3.1 constitutes a potential target for treating AD by reducing ...
Bushong, Trevor, Chavez, Monique, Jin, Lee-Way, Lucente, Jacopo Di, Maezawa, Izumi, Nguyen, Hai M, Singh, Latika, Singh, Vikrant, Wulff, Heike   +8 more
core   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Artificial intelligence in COVID-19 drug repurposing

The Lancet: Digital Health, 2020
Summary: Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19.
Yadi Zhou, PhD, Fei Wang, ProfPhD, Jian Tang, ProfPhD, Ruth Nussinov, ProfPhD, Feixiong Cheng, ProfPhD   +4 more
doaj   +1 more source

Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing [PDF]

, 2019
Trypanosoma cruzi is the causative agent of Chagas disease, a parasitic infection endemic in Latin America. In T. cruzi the transport of polyamines is essential because this organism is unable to synthesize these compounds de novo.
Martínez Sayé, Melisa Soledad, Miranda, Mariana Reneé, Pereira, Claudio Alejandro, Phanstiel, Otto, Reigada, Chantal, Valera Vera, Edward Augusto   +5 more
core   +1 more source

Drug repurposing in cancer

Pharmacological Research, 2017
Cancer is a major health issue worldwide, and the global burden of cancer is expected to increase in the coming years. Whereas the limited success with current therapies has driven huge investments into drug development, the average number of FDA approvals per year has declined since the 1990s.
Linda, Sleire, Hilde Elise, Førde, Inger Anne, Netland, Lina, Leiss, Bente Sandvei, Skeie, Per Øyvind, Enger   +5 more
openaire   +2 more sources

Digital twins to accelerate target identification and drug development for immune‐mediated disorders

FEBS Open Bio, EarlyView.
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley   +1 more source

A Unified Explanation for Drug Repurposing and Pharmacological Pleiotropy Based on Classical and Statistical Thermodynamics

Pharmacology Research & Perspectives
Drug repurposing is an authentic, emerging, and growing aspect of drug development when the demand for new therapeutic solutions is high. Many repurposed drugs have been discovered by serendipity or a non‐ordered process driven by chance and sharp ...
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
doaj   +1 more source